Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Moderna (NASDAQ:MRNA) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 9:00 a.m. ET. A live webcast can be accessed in the 'Events and Presentations' section of its investors website, with a replay available for 30 days post-event. Over the past decade, Moderna has evolved from a research company to a leader in mRNA therapeutics and vaccines, significantly contributing to COVID-19 solutions. For more information, visit modernatx.com.

CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1^st at 9:00 a.m. ET.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Moderna Contacts:

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/729136/Moderna-to-Present-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference

FAQ

What is Moderna's participation in the Piper Sandler 34th Annual Healthcare Conference?

Moderna will participate in a fireside chat on December 1, 2022, at 9:00 a.m. ET.

Where can I watch the Moderna presentation from the Piper Sandler conference?

The presentation will be available via live webcast in the 'Events and Presentations' section of Moderna's investors website.

How long will the Moderna webcast be available after the conference?

A replay of the webcast will be archived for at least 30 days after the presentation.

What has been Moderna's impact in the biotech industry?

Moderna has transformed its business and significantly contributed to COVID-19 vaccine development, leveraging its mRNA platform.

What does Moderna focus on in its research and development?

Moderna focuses on mRNA therapeutics and vaccines for infectious diseases, immuno-oncology, and various other health conditions.